Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

NCT05537922 is registered in ClinicalTrials.gov with Fondazione IRCCS Istituto Nazionale dei Tumori, Milano as lead sponsor.

NCT NCT05537922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05537922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase
Observational
Overall status
Recruiting
Start date
October 1, 2022
Completion date
October 1, 2027
Enrollment
2,200 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lung adenocarcinoma, lung cancer metastatic, lung cancer, nonsmall cell, non small cell lung cancer